With a focus on determining if specific antidiabetic medication could predict the risk of Alzheimer’s disease in patients with T2DM mellitus, it was determined the GLP-1 analogs and rosiglitazone demonstrated a reduction in risk of developing AD. Here, GLP1R is linked to early-onset autosomal dominant Alzheimer disease.